title: Nonoxynol-9 vaginal pessary: a preliminary Indian experience.
abstract: BACKGROUND
  Barrier methods of contraception do not have systemic effects and allow the user complete control over their use. For women, the ease of use of a contraceptive is often more important than its efficacy. Hence, barrier methods could be offered as a useful alternative method of contraception. Nonoxynol-9 (a spermicide) is a locally acting, non-hormonal method free from systemic side-efforts. It is a woman-controlled, reversible method which is to be used before intercourse. There are little data available on its efficacy, side-effects and acceptability among Indian women.
  
  
  METHODS
  The vaginal pessary nonoxynol-9 was offered as a contraceptive option to 3200 women attending the Family Planning clinics at 31 Human Reproduction Research Centres (HRRCs) of the Indian Council of Medical Research. The other contraceptives offered included an intrauterine device, oral pills, condoms, Norplant, tubal sterilization and vasectomy using the cafeteria approach. Those who accepted nonoxynol-9 were followed up to assess the rates of continuation, failure and side-effects.
  
  
  RESULTS
  The nonoxynol-9 pessary was accepted by 541 women who were followed up for 3470 woman-months of use. The reasons given for acceptance were that it was user-controlled and/or they did not wish to use other methods because of the side-effects or contraindications of these methods. The overall continuation rates were 41.2% and 33% at 9 and 12 months of use, respectively. Most women (31.3%) discontinued its use due to personal reasons such as husband dissatisfaction, desire for further pregnancy, irregular use of pessary and difficulty in insertion. Twenty-nine women became pregnant during the study period (15 due to method failure and 14 due to user failure) giving a use-effectiveness of 8.8% at 12 months. The method failure rate was 4.3% at 12 months of use. The failure rates were lower compared with the reported failure rates of barrier contraceptives (1%-30% at 1 year of use) and the side-effects were minimal.
  
  
  CONCLUSIONS
  Nonoxynol-9 had low acceptability (16.9%) and overall continuation rates--41.2% and 33% at 9 and 12 months of use. It could be offered to women looking for a short term, user-controlled contraceptive.
authors.affiliation: Division of Reproductive Health and Nutrition, Indian Council of Medical Research, Ansari Nagar, New Delhi.
authors.forename: S C
authors.initials: SC
authors.lastname: Yadav
authors.forename: L N
authors.initials: LN
authors.lastname: Gaur
authors.forename: Neeru
authors.initials: N
authors.lastname: Gupta
authors.forename: Malabika
authors.initials: M
authors.lastname: Roy
authors.forename: N C
authors.initials: NC
authors.lastname: Saxena
mesh_terms: D000293:Adolescent; D000328:Adult; D003267:Contraception; D005193:Family Planning Services / Q000379:methods; D005260:Female; D006801:Humans; D007194:India; D017137:Nonoxynol / Q000009:adverse effects / Q000627:therapeutic use*; D010342:Patient Acceptance of Health Care / Q000706:statistics & numerical data*; D010549:Personal Satisfaction; D010570:Pessaries; D013089:Spermatocidal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017211:Treatment Failure
chemical_list: D013089:Spermatocidal Agents; D017137:Nonoxynol